Effect of frailty on prognosis in patients with metastatic prostate cancer(FRA-PmC study)

An study of the effect of frailty on prognosis in patients with metastatic prostate cancer - An study of the effect of frailty on prognosis in patients with metastatic prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039864

Enrollment

200

Registered

2020-03-19

Start date

2017-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with metastatic prostate cancer who were treated with standard of care

Exclusion criteria

Exclusion criteria: Not eligible for the standard of care

Design outcomes

Primary

Measure	Time frame
The primary outcome was the effect of frailty on progression-free survival in patients mHNPC and mCRPC.	—

Secondary

Measure	Time frame
Secondary outcomes included safety, overall survival.	—

Countries

Japan

Contacts

Public ContactShingo Hatakeyama

Hirosaki University School of Medicine Urology

shingorilla2@gmail.com0172395091

Outcome results